AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04502524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational and reminder text messages
Study NCT04502524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04502524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06319612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06319612 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06319612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.
Study NCT06319612 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline is used. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT05355753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFT8634
Description: Oral dose of CFT8634
Study NCT04034615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchyme Stem Cells high-dose group
Description: Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study NCT04034615 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
Study NCT05883878 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PRS
Description: genetic test for the evaluation of PRS cardiovascular risk
Study NCT05883878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital app and wearable device
Description: a wearable device connected with its app
Study NCT06123156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildénafil during 10 months (50mg daily), start 30 days after surgery
Study NCT06123156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 platelet during 10 months (daily), start 30 days after surgery
Study NCT05422521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples and 18FDG PET-CT exams
Description: * 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month)~* blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)
Study NCT06544941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Bassinet
Description: The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
Study NCT06544941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HALO
Description: The HALO is a commercially available bassinet
Study NCT06623643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The investigation of melatonin and cortisol levels in the saliva
Description: In the related study, patient data from individuals who visited the Oral and Maxillofacial Radiology clinic at Van Yüzüncü Yıl University Faculty of Dentistry with complaints of bruxism will be used. The diagnosis of bruxism will be made based on clinical data. Diagnoses will be made by Dr. Sema KAYA using clinical findings such as patient history used for the current diagnosis of bruxism, tooth wear, tooth mobility, pain in the temporomandibular joint (TMJ), headaches, pain in the chewing muscles, hypertrophy, and a feeling of fatigue. Before taking the saliva samples, patients will be asked to rinse their mouths with sterile water, and then they will be asked to spit into sterile plastic containers. After approximately 3 mL of saliva is collected, it will be transferred to appropriate Eppendorf tubes and stored at -80°C. Melatonin and cortisol levels will later be analyzed using the enzyme-linked immunosorbent assay (ELISA) method.
Study NCT05378360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
Study NCT05378360 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DWP708
Description: Placebo Comparator: Placebo of DWP708 / BID / up to 28 days Experimental: DWP708 10 ug/g / BID / up to 28 days Experimental: DWP708 20 ug/g / BID / up to 28 days Experimental: DWP708 40 ug/g / BID / up to 28 days
Study NCT06264960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy
Description: After the patient was admitted to the angiography laboratory, approximately 10 minutes before the angiography procedure commenced, they were seated and allowed to relax. Music was played using a digital MP3 player.
Study NCT06264960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Individuals in the breathing exercise group were made to do breathing exercises by the researcher in the patient room 30 minutes before coronary angiography. The exercises were performed in a single patient room, in a quiet and calm environment. During the first 5 minutes, the researcher explained how the exercise was done with pictures and showed it to the patient. The patient was then asked to do the exercise for 10 minutes under the supervision of the researcher.
Study NCT04774705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )
Description: A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.
Study NCT04774705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.
Study NCT06070363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Description: Acupuncture Needle Insertion
Study NCT05232786 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT06015282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational aQIVc
Description: Investigational MF59 Adjuvanted Cell-derived Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT06015282 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: licensed QIV1
Description: Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study NCT05928741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload
Description: Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
Study NCT04691661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib HCl 50 mg
Description: Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
Study NCT04691661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04700787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: sulopenem intravenous 1000 mg on Day 1 and then sulopenem etzadroxil/probenecid oral 500 mg/500 mg on Day 2
Study NCT05664919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA58 Nasal Spray
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Study NCT06328387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The dosage of hydroxychloroquine is determined based on the dose escalation study, and the appropriate administration method will be determined based on this result.
Study NCT06328387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
Study NCT06328387 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sacituzumab Govitecan
Description: Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them.
Study NCT06328387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study NCT06328387 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study NCT05593549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Trehalose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Study NCT05593549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose will be given at a dose of 10g mixed in 500 mL of water to be consumed 1 time per day for 14 days
Study NCT05537987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: 3+3 dose escalation
Study NCT06406153 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Laronidase
Description: Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
Study NCT06406153 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: Laronidase as Aldurazyme® (the first 12 weeks) or YW17 (the second 12 weeks) is administered.
Study NCT06406153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: An antihistamine is administered one hour before the infusion.
Study NCT06406153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: An antihistamine is administered one hour before the infusion.
Study NCT06015282 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: licensed QIV2
Description: Licensed, Quadrivalent Influenza Vaccine containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO for quadrivalent vaccines for the respective season.
Study NCT04596891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
Study NCT06098079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone-Bupropion (NB) Combination
Description: A total daily dosage of two NB 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
Study NCT06098079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total daily dosage of two placebo tablets twice daily (in an identical, non-medicine containing tablet) is reached at the start of Week 4.
Study NCT06649149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genially
Description: In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
Study NCT05917886 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auditory beat stimulation: 8Hz monaural beat stimulation
Description: Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
Study NCT05917886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory beat stimulation: 8Hz monaural beat stimulation
Description: Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
Study NCT05809310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (stent) for PA stenosis
Description: Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
Study NCT05282212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Scan
Description: Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
Study NCT05446948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: beveled 27G+ vitrectomy system
Description: The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
Study NCT05446948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 25G+ vitrectomy system
Description: The device is a traditional instrument, and its probe tip is flat.
Study NCT05703438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritionally balanced low-calorie diet
Description: Dietary interventions were given with a calorie deficit of 500-600 kcal from the participants' usual daily intake.
Study NCT06406153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipyretic
Description: An antipyretic is administered one hour before the infusion.
Study NCT06406153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipyretic
Description: An antipyretic is administered one hour before the infusion.
Study NCT06171932 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone,
Description: No intervention required
Study NCT06649149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
Study NCT05022485 — intervention group
Intervention type: DEVICE
Intervention: ZNN Bactiguard tibia
Description: Tibia fracture fixation
Study NCT05096663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cobalamin
Description: Given intramuscularly
Study NCT05096663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given orally (PO)
Study NCT05096663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT05096663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Given PO
Study NCT05096663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT05096663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nogapendekin Alfa
Description: Given SC
Study NCT05096663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05096663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV
Study NCT05096663 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study NCT05580536 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project Dulce + Dulce Digital
Description: Project Dulce is a 5-week curriculum, group diabetes self-management education and support, program delivered by a peer educator in Arabic.~The curriculum provides knowledge as well as skills and tools needed to change behaviors and adapt to a life with type 2 diabetes.~The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring as well as the genetics contribution to diabetes development. It is presented over 5 weeks where participants will learn and practice diabetes self-management skills, and help one another address family, cultural, or health system barriers to managing their diabetes. .~Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Arabic.
Study NCT03068832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized peptide vaccine
Description: -It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
Study NCT03068832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
Study NCT03068832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * After trial enrollment and up to 7 days after the 1st vaccine dose~* 2 weeks after last dose~* Time of progression or discontinuation
Study NCT06506695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Craniofacial implant placement
Description: * Resection of oncologic process or remnants after trauma if necessary~* Placement of craniofacial implants in the nasal floor and/or the temporal bone.~* Placement of split thickness skin graft around the implants~* Placement of nose and/or ear prosthesis within 3 weeks
Study NCT05707741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexmetomedine infusion
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,
Study NCT05707741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmetomedine infusion
Description: 50 ml mixture of saline 49 ml and dexmedetomidine 100 μg,